Table 3.
Correlation between NLR value with clinicopathological features in prostate cancer
| Patients and tumor characteristics | n(%) | NLR | χ2 | P-value | |
|---|---|---|---|---|---|
| ≤3.3 | >3.3 | ||||
| PSA level (ng/ml) | |||||
| < 10 | 19 (25.3) | 12 (63.2) | 7 (36.8) | 8.248 | 0.016 |
| 10 ~ 20 | 29 (38.7) | 14 (48.3) | 15 (51.7) | ||
| > 20 | 27 (36.0) | 6 (22.2) | 21 (77.8) | ||
| Gleason score | |||||
| ≤ 6 | 14 (18.7) | 10 (71.4) | 4 (28.6) | 6.797 | 0.033 |
| 7 | 28 (37.3) | 12 (42.9) | 16 (57.1) | ||
| 8 ~ 10 | 33 (44.0) | 10 (30.3) | 23 (69.7) | ||
| T stage | |||||
| T1–2 | 33 (44.0) | 21 (63.6) | 12 (36.4) | 10.593 | 0.001 |
| T3–4 | 42 (56.0) | 11 (26.2) | 31 (73.8) | ||
| Lymph node metastasis | |||||
| N0 | 46 (61.3) | 27 (58.7) | 19 (41.3) | 12.495 | 0.000 |
| N1 | 29 (38.7) | 5 (17.2) | 24 (82.8) | ||
| Distant metastasis | |||||
| M0 | 43 (57.3) | 25 (58.1) | 18 (41.9) | 9.863 | 0.002 |
| M1 | 32 (42.7) | 7 (21.9) | 25 (78.1) | ||
| TNM stage | |||||
| Stage II | 26 (34.7) | 17 (65.4) | 9 (34.6) | 8.396 | 0.004 |
| Stage III ~ IV | 49 (65.3) | 15 (30.6) | 34 (69.4) | ||
NLR neutrophil-to-lymphocyte ratio, PSA prostate specific antigen